RT Journal Article
SR Electronic
T1 PROTOCOL OF A SYSTEMATIC REVIEW AND METAANALYSIS OF CASE-SERIES AND CASE-REPORTS INVOLVING GLUCAGON IN BETA-BLOCKER OVERDOSE
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.22.23291720
DO 10.1101/2023.06.22.23291720
A1 Domene, Ramón Aranda
A1 Esteban-Blanes, Alberto
YR 2023
UL http://medrxiv.org/content/early/2023/06/22/2023.06.22.23291720.abstract
AB The utility of glucagon in human myocardium remains controversial. In the past, some articles have reported inotropic and chronotropic effects of glucagon on the heart, but other studies have found no significant effects. The main cardiovascular indication for glucagon is beta-blocker toxicity (BB), which is listed as recommendation IIb in some guidelines on the basis of some experimental studies and case reports. To our knowledge, no systematic review has been published analyzing the outcomes of glucagon in reports of overdose. This study will attempt to incorporate findings from case series and reports to fill the gap on a topic where experimental and comparative studies have already been conducted. A protocol to the development of this work is provided.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors